FDA Worried Your Blood Transfusion Might Come With Malaria
Published Date: 1/16/2025
Notice
Summary
The FDA is rolling out new draft rules to help blood banks better spot and stop malaria from sneaking into blood donations. Blood centers will start using special tests to check donors who might have malaria, making transfusions safer for everyone. If you’re involved in blood collection, get ready to share your thoughts by March 17, 2025, before these changes become official!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Selective NAT Testing for At‑Risk Donors
The FDA’s draft guidance recommends that blood establishments selectively test donations from donors at risk for malaria using an FDA-licensed donor screening nucleic acid test (NAT) for Plasmodium species. This recommendation applies to the collection of Whole Blood and blood components and is intended to replace the December 2022 recommendations when finalized.
Reduced Risk of Transfusion‑Transmitted Malaria
If blood donations from donors at risk for malaria are selectively tested with an FDA-licensed donor screening NAT for Plasmodium species, transfusion recipients should face a lower risk of transfusion-transmitted malaria (TTM). The draft guidance is intended to supersede the December 2022 recommendations if finalized.
Source Plasma Collections Are Exempt
The draft guidance does not recommend screening Source Plasma donors for malaria risk factors because Source Plasma undergoes manufacturing steps that remove or inactivate pathogens and licensed plasma derivatives from Source Plasma have not transmitted malaria. The guidance’s recommendations apply to Whole Blood and blood components, except Source Plasma.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-17562, Arms Sales Notification
The DoD (referred to herein as "the Department," "Department of War" or "DoW") is publishing the unclassified text of an arms sales notification.
2026-17589, Leila Kump, M.D.; Decision and Order
2026-17633, Combined Notice of Filings
2026-17618, Oil Country Tubular Goods From Austria, Taiwan, and the United Arab Emirates: Postponement of Preliminary Determinations in the Less-Than-Fair-Value Investigations
2026-17634, Combined Notice of Filings #2
2026-17547, Self-Regulatory Organizations; Nasdaq ISE, LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Delay the Implementation of SR-ISE-2026-18
Previous / Next Documents
Previous: 2025-01027, Proposal to Refuse to Approve a New Drug Application for TRADIPITANT; Opportunity for a Hearing
The FDA is thinking about saying no to Vanda Pharmaceuticals' new drug, TRADIPITANT, in its current form. Vanda can ask for a hearing to explain why the drug should be approved. If you want to speak up or support the hearing, you’ve got until mid-February and mid-March 2025 to send in your requests and info.
Next: 2025-01029, United States Classes, Standards, and Grades for Poultry
The USDA is updating the rules that decide how poultry is classified and graded to keep up with new farming methods and what shoppers want. This affects poultry producers, sellers, and buyers who rely on clear quality standards. You can share your thoughts by March 17, 2025, so get ready to weigh in and help shape the future of poultry labeling!